Correll, CU, Rummel-Kluge, C, Corves, C, Kane, JM, Leucht, S.
Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull
2009; 35: 443–57.
Harrington, M, Lelliott, P, Paton, C, Okocha, C, Duffett, R, Sensky, T.
The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatr Bull
2002; 26: 414–8.
Munro, J, Matthiasson, P, Osborne, S, Travis, M, Purcell, S, Cobb, AM, et al.
Amisulpiride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand
2004; 110: 292–8.
Josiassen, RC, Joseph, A, Kohegyi, E, Stokes, S, Dadvand, M, Paing, WW, et al.
Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry
2005; 162: 130–6.
Honer, WG, Thornton, AE, Chen, EY, Chan, RC, Wong, JO, Bergmann, A, et al.
Clozapine alone versus clozapine and risperidone with refractory schizophrenia. New Engl J Med
2006; 354: 472–82.
Pai, NB, Laidlaw, M, Vella, SC. Augmentation of clozapine with another pharmacological agent: treatment for refractory schizophrenia in the ‘real world’. Acta Psychiatr Scand
2012; 126: 40–6.
Taylor, DM, Smith, L, Gee, SH, Nielsen, J.
Augmentation of clozapine with a second antipsychotic: a meta-analysis. Acta Psychiatr Scand
2012; 125: 15–24.
Sandson, NB, Cozza, KL, Armstrong, SC, Eckermann, G, Fischer, BA, Phillips, B.
Clozapine case series. Psychosomatics
2007; 48: 170–5.
Godleski, LS, Sernyak, MJ. Agranulocytosis after addition of risperidone to clozapine treatment (letter). Am J Psychiatry
1996; 153: 735–6.
Friedman, J, Ault, K, Powchik, P.
Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiatry
1997; 42: 522–3.
Waddington, JL, Youssef, HA, Kinsella, A.
Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry
1998; 173: 325–9.
Antipsychotic polypharmacy – confusion reigns. Psychiatrist
2010; 34: 41–3.
Odelola, D, Ranceva, N.
Polypharmacy: saint or sinner? (letter)
2010; 34: 354.
Lepping, P, Harborne, GC. Polypharmacy: how bad are we really? (letter)
2010; 34: 208–9.
Reilly, JG, Ayis, SA, Ferrier, IN, Jones, SJ, Thomas, SH. QT interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet
2000; 355: 1048–52.
Taylor, D, Paton, C, Kapur, S.
Clozapine augmentation. In The Maudsley Prescribing Guidelines in Psychiatry (11th edn): 66–8. Wiley-Blackwell, 2012.
Tungaraza, TE, Gupta, S, Jones, J, Poole, R, Slegg, G.
Polypharmacy and high-dose antipsychotic regimes in the community. Psychiatrist
2010; 34: 44–6.